Ad
related to: i-131 treatment for thyroid cancer- DTC Treatment Option
HCPs: Learn About An Option For
Differentiated Thyroid Cancer.
- Dosing Information
Download A Dosing Guide &
View Safety Information.
- Co-Pay Program
View Co-Pay Information
For Eligible DTC Patients.
- Mechanism of Action
Learn More About The MOA
And View Safety Information.
- Access & Support
Learn About A Support Program
For Your Eligible DTC Patients.
- Video Resources
View Videos For HCPs &
Hear Clinical Perspectives.
- DTC Treatment Option
Search results
Results From The WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
Thyroid blockade with (nonradioactive) potassium iodide is indicated for nuclear medicine scintigraphy with iobenguane/mIBG. This competitively inhibits radioiodine uptake, preventing excessive radioiodine levels in the thyroid and minimizing risk of thyroid ablation (in treatment with 131 I). The minimal risk of thyroid cancer is also reduced ...
The iodide ion is selectively taken up by the thyroid gland. Both benign conditions like thyrotoxicosis and certain malignant conditions like papillary thyroid cancer can be treated with the radiation emitted by radioiodine. [6] Iodine-131 produces beta and gamma radiation. The beta radiation released damages both normal thyroid tissue and any ...
In this procedure, 131 I is administered either intravenously or orally following a diagnostic scan. This procedure may also be used, with higher doses of radio-iodine, to treat patients with thyroid cancer. The 131 I is taken up into thyroid tissue and concentrated there. The beta particles emitted by the radioisotope destroys the associated ...
Radiation-induced thyroiditis is a form of painful, acute thyroiditis resulting from radioactive therapy to treat hyperthyroidism or from radiation to treat head and neck cancer or lymphoma. It affects 1% of those who have received radioactive iodine (I-131) therapy for Graves' Disease, typically presenting between 5 and 10 days after the ...
Thyroid neoplasm is a neoplasm or tumor of the thyroid. It can be a benign tumor such as thyroid adenoma, [1] or it can be a malignant neoplasm (thyroid cancer), such as papillary, follicular, medullary or anaplastic thyroid cancer. [2] Most patients are 25 to 65 years of age when first diagnosed; women are more affected than men.
This is a form of targeted therapy for hyperthyroidism. Since even low levels of ionizing radiation are highly mutagenic and can cause cancer, [16] less toxic iodine isotopes such as iodine-123 [17] are more commonly used in nuclear imaging, while iodine-131 is used for its cytolytic (cell-destroying) effects in hyperthyroidism and thyroid ...
The patient swallows a radioisotope of iodine in the form of capsule or fluid, and the absorption (uptake) of this radiotracer by the thyroid is studied after 4–6 hours and after 24 hours with the aid of a scintillation counter. The dose is typically 0.15–0.37 MBq (4–10 μCi) of 131 I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123 I ...
Ad
related to: i-131 treatment for thyroid cancer